Tale Of Two ALS Drugs: Similar Study Design, Different Take By US FDA

 
• By Brenda Sandburg

Amylyx’s AMX0035 and Mitsubishi’s edaravone showed similar treatment effect on ALS versus placebo in a single study, but the FDA found edaravone’s results to be more robust and supported by secondary endpoints.

Path fork
US FDA takes different paths in review of two ALS drugs • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers